Capital Markets Day: Commercial Execution and Innovation in Obesity Care
19
Commercial execution and innovation
Obesity care
Novo NordiskⓇ
In a 20-week, phase 1 trial, CagriSema showed weight loss of
17% and appeared to have a safe and well tolerated profile
Weight loss for different doses of CagriSema in phase 1
The GI profile appeared similar to semaglutide 2.4 monotherapy
Change in
body weight
0
-5
-10
Last dosing
AEs
n=12 n=12 n=12
n=12 n=12 n=11 n=24
N (%)
N (%)
N (%)
N (%) N (%)
N (%)
N (%)
11 (92) 12 (100) 11 (92) 12 (100) 12 (100) 11 (100) 23 (96)
SAES1
0
0
0
1(8)
0
0
0
AEs leading to
withdrawal
1 (8)
0
0
1 (8)
0
0
0
-15
GI disorders
7 (58) 10 (83) 7 (58) 10 (83) 11 (92) 9 (82) 19 (79)
0
14
28 42 56 70 84 98 112 126 140
Follow-up
Time since first dosing (days)
Cagri 0.16 mg,
Cagri 0.3 mg,
Sema 2.4 mg
Sema 2.4 mg
Cagri 0.6 mg,
Sema 2.4 mg
Cagri 1.2 mg,
Sema 2.4 mg
Cagri 2.4 mg,
Sema 2.4 mg
Cagri 4.5 mg,
Sema 2.4 mg
✗ Placebo,
Sema 2.4 mg
1 The serious adverse event was meningitis
CagriSema: Cagrilintide in combination with semaglutide; Cagri: Cagrilintide; Sema: semaglutide; SAE: Serious adverse events; GI: Gastro-intestinal
Change in body weight is analysed using a mixed model for repeated measurements, where all changes from baseline in body weight measurements enter as the dependent variables and treatment, visit and baseline body weight enter as fixed effects.
Treatment and baseline body weight are nested within visit.
Source: Adapted from Enebo et al. Lancet. 2021 May 8;397(10286):1736-1748.
CMD22
CAPITAL MARKETS DAYView entire presentation